Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebuliser in Adult Patients with Mild To Moderate Persistent Asthma.

Trial Profile

Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebuliser in Adult Patients with Mild To Moderate Persistent Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Budesonide (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Verus Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2017 Status changed from recruiting to completed (Global end Date:22-02-2007).
    • 21 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top